Sign Out
Symptomatic treatment of osteoarthritis (OA): The usual recommended dose of celecoxib is 200 mg administered as a single dose. In some patients, with insufficient relief from symptoms, an increased dose of 200 mg twice daily may increase efficacy. In the absence of an increase in therapeutic benefit after 2 weeks, other therapeutic options should be considered.
Symptomatic treatment of rheumatoid arthritis (RA): The recommended dose of celecoxib is 200 mg twice per day.
Ankylosing Spondylitis (AS): The recommended dose of celecoxib is 200 mg administered as a single dose. Some patients may benefit from a total daily dose of 400 mg.
Management of acute pain: The recommended dose of celecoxib is 400 mg initially, followed by an additional 200 mg dose, if needed on the first day. On subsequent days, the recommended dose is 200 mg twice daily or 400 mg once daily as needed.
Treatment of primary dysmenorrhea: The recommended dose of celecoxib is 400 mg initially, followed by an additional 200 mg dose, if needed on the first day. On subsequent days, the recommended dose is 200 mg twice daily or 400 mg once daily as needed.
Low back pain: The recommended dose of celecoxib is 200 mg or 400 mg daily, administered as a 200 mg single dose, or as 100 or 200 mg twice per day. Some patients may benefit from a total daily dose of 400 mg.
Renal Impairment: Mild or moderate impairment: There are no dosage adjustments.
Severe impairment: Use is not recommended.
Advanced renal disease: Use is not recommended.
Abnormal renal function tests (persistent or worsening): Discontinue use.
Hepatic Impairment: Mild impairment (Child-Pugh class A): No dose adjustment necessary.
Moderate impairment (Child-Pugh class B): Reduce dose by 50%.
Severe impairment (Child-Pugh class C): Use is not recommended.
Abnormal liver function tests (persistent or worsening): Discontinue use.
Mode of Administration: Celecoxib is administered orally as a single daily dose or in 2 equally divided doses daily. May be administered without regard to meals.
